BRÈVE

sur MindBio Therapeutics (isin : CA60256C1086)

MindBio Therapeutics Enters $66.5 Million Deal with Enveric Biosciences for Psilocin Prodrug Development

MindBio Therapeutics, a clinical stage biopharma company, announced a non-binding term sheet with Enveric Biosciences to out-license a Novel Psilocin Prodrugs (NPP) class for neuropsychiatric treatments. This pre-agreement could lead to a definitive $66.5 million collaboration focusing on microdosing to mitigate the hallucinogenic effects of psychedelics.

The term sheet specifies that MindBio will harbor exclusive, global licensing rights to develop and commercialize the NPP for conditions such as depression. Success in negotiations will involve milestone payments and royalties to Enveric. These NPPs are engineered for controlled psilocin release, potentially providing a new treatment avenue for mental health disorders.

Joseph Tucker, Enveric's CEO, expressed optimism about the partnership's potential to harness psychedelic compounds for acute neuropsychiatric conditions. Justin Hanka, CEO of MindBio, highlighted the strategic fit of the NPP with their microdosing-focused innovation agenda and the plan to progress the drug to clinical trials.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de MindBio Therapeutics